Merck seeks more approvals for infectious disease drug

Pharma giant Merck is looking to bag more indications for its cytomegalovirus (CMV) treatment Prevymis.

The pharma announced on Friday that the FDA has accepted two NDAs for the drug, also known as letermovir. Merck is hoping to grab another indication to be used in the prevention of CMV disease in adults who receive kidney transplants. The FDA has set the PDUFA date for June 5.